NASDAQ$MRVI
Maravai LifeSciences Holdings Inc. · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2025.
Maravai LifeSciences reported first-quarter 2025 revenue of $46.9 million, exceeding guidance. However, the company experienced a net loss of $(52.9) million and negative Adjusted EBITDA of $(10.5) million, primarily due to a lack of high-volume CleanCap orders and lower research product demand in Nucleic Acid Production, as well as a goodwill impairment charge.
- First quarter 2025 revenue was $46.9 million, a 27.0% decrease year-over-year.
- Nucleic Acid Production revenue decreased by 37.5% year-over-year to $28.8 million.
- Biologics Safety Testing revenue was relatively flat year-over-year at $18.1 million.
- Reported a net loss of $(52.9) million and Adjusted EBITDA of $(10.5) million for the quarter.
Headline financials
Revenue & EPS history
Maravai · Revenue · Quarterly
$46.9M
Revenue by segment
Maravai · $66.9M total across 2 segments · Q3 2023
- TriLink$51.2M-70.7%76.6%
- Cygnus$15.6M-4.5%23.4%
Forward guidance
Maravai's revenue guidance for the full year 2025 remains unchanged in the range of $185.0 million to $205.0 million. This guidance is based on expectations for the existing base business and excludes potential high-volume CleanCap orders for commercial vaccine programs or potential new acquisitions.
Tailwinds
- First quarter revenue exceeded guidance range.
- Base business revenue grew compared to the fourth quarter of 2024.
- Commitment to return-to-growth strategy.
- Customer focus, differentiated technologies, and GMP services support clients from discovery through commercialization.
- Positioned to navigate the evolving landscape and drive long-term value.
Headwinds
- Revenue guidance for the full year 2025 does not include revenue from high-volume CleanCap orders for commercial phase vaccine programs.
- Guidance does not include potential new acquisitions.
- Guidance is subject to a number of risks and uncertainties.
- Dynamic and shifting macroeconomic environment.
- Reliance on a limited number of customers for a high percentage of revenue.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
-0.2%
Avg return
Earnings day
+2.1%
Avg return
5 days after
-0.1%
Avg return
30 days after
42%
10 / 24 earnings
Positive
+58.9%
Q4 2023
Best reaction
-36.7%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +23.1% | +10.7% | — | |
| Q4 2025 | +9.9% | +13.2% | -12.3% | |
| Q3 2025 | -0.7% | +12.5% | +28.0% | |
| Q1 2025 | -2.4% | -0.9% | +6.6% | |
| Q4 2024 | -6.4% | -13.2% | -31.4% | |
| Q3 2024 | -36.7% | -29.0% | -37.1% | |
| Q2 2024 | -6.7% | -4.3% | -0.4% | |
| Q1 2024 | +10.0% | +17.5% | -3.9% | |
| Q4 2023 | +58.9% | +57.0% | +66.5% | |
| Q3 2023 | -31.3% | -25.0% | -24.3% | |
| Q2 2023 | -3.5% | -10.1% | -5.7% | |
| Q1 2023 | -16.4% | +2.5% | -3.3% | |
| Q4 2022 | +6.9% | +3.2% | -2.4% | |
| Q3 2022 | -11.7% | -13.8% | -15.3% | |
| Q2 2022 | +2.2% | -3.5% | -20.7% | |
| Q1 2022 | +6.1% | -2.9% | +6.7% | |
| Q4 2019 | +1.4% | +1.1% | -9.7% | |
| Q4 2021 | -1.6% | +14.8% | +7.0% | |
| Q3 2020 | -1.7% | -0.4% | +6.3% | |
| Q3 2021 | +1.6% | +3.1% | +10.1% | |
| Q2 2021 | -5.7% | +8.8% | +0.6% | |
| Q1 2020 | +4.0% | +8.6% | +26.5% | |
| Q1 2021 | -4.8% | +2.1% | +13.1% | |
| Q4 2020 | -0.4% | -2.4% | -6.3% | |
| Q2 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro